ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a non-hematopoietic erythropoietin
analogue, ARA 290, exerts beneficial effects on blood glucose levels and insulin secretion in
persons with prediabetes (impaired glucose tolerance, IGT, or impaired fasting glucose, IFG),
or drug-naive type 2 diabetes.
The study will also evaluate effects of ARA 290 on insulin sensitivity and serum levels of
inflammatory agents, e.g. cytokines. In addition, safety will be monitored by following
parameters related to hematology, kidney and liver function and lipid levels.